Key Clinical Summary: Applying Evidence-Based Antithrombotic Strategies

This is a micro-learning module summary of a presentation by Dr. Jeffrey L. Saver which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This program is supported by an independent education grant from Bayer. This education program is only available to healthcare professionals in the USA.

Secondary prevention following a non-cardioembolic ischemic stroke or transient ischemic attack (TIA) requires a precision-based approach. Modern strategies have shifted from uniform long-term monotherapy to intensive, short-term dual antiplatelet therapy (DAPT) tailored to the patient’s clinical presentation, timing, and genetic profile.

Standard DAPT for Minor Stroke and High-Risk TIA

The risk of recurrent stroke is highly "front-loaded," with the greatest hazard occurring within the first three weeks post-event. Current guidelines recommend early initiation of intensive antiplatelet therapy to mitigate this risk.

• Recommended Regimen: For patients with a minor non-cardioembolic ischemic stroke (NIHSS score ≤3) or high-risk TIA (ABCD2 score ≥4) who did not receive intravenous thrombolysis (IVT), the standard of care is DAPT using aspirin and clopidogrel.
• Timing and Duration: DAPT should be initiated within 24 hours of symptom onset and continued for 21 days.
• Transition to Monotherapy: After 21 days, patients should switch to single antiplatelet therapy (SAPT). Clinical trials like CHANCE and POINT demonstrate that the benefit of double therapy in reducing recurrence is concentrated in these first three weeks, after which the increased risk of hemorrhage offsets the ischemic benefit.

Addressing Clopidogrel Resistance (CYP2C19 Loss-of-Function)

Resistance to clopidogrel is a significant clinical concern, particularly in Asian populations, due to the presence of the CYP2C19 loss-of-function allele.

• Regimen Adjustment: For carriers of the loss-of-function allele with minor stroke or high-risk TIA, DAPT with aspirin and ticagrelor for 21 days (followed by ticagrelor monotherapy) is preferred over the aspirin/clopidogrel combination.
• Evidence Basis: The CHANCE 2 trial confirmed that in these genetic carriers, the ticagrelor-based regimen substantially reduces event rates compared to clopidogrel-based regimens, with the benefit again concentrated in the early weeks.

Ticagrelor as an Alternative Regimen

In cases where ticagrelor is used, its role is also supported for a slightly broader patient population.

• Expanded NIHSS Criteria: Guidelines indicate that for recent minor ischemic stroke (NIHSS ≤5) or high-risk TIA (ABCD2 ≥6 or symptomatic stenosis ≥50%), DAPT with ticagrelor and aspirin for 30 days may be considered.
• Considerations: While effective, this regimen is often considered a secondary option to aspirin/clopidogrel due to a higher rate of complications, unless genetic resistance to clopidogrel is present.

Clinical Conclusion for Practice

To optimize secondary prevention and balance the tradeoff between thrombosis and hemorrhage:

1. Initiate early: Antiplatelet therapy should ideally begin within 24 hours.
2. Limit DAPT duration: For most minor strokes and TIAs, 21 days is the evidence-based window for double therapy.
3. Tailor to genetics: Use CYP2C19 genotyping when possible to identify clopidogrel non-responders and switch to ticagrelor-based DAPT if a loss-of-function allele is detected.

Content is accurate as of the date of release.